- Home
- TWO vs XERS Comparison
TWO vs XERS Comparison
Compare TWO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWO
- XERS
- Stock Information
- Founded
- TWO 2009
- XERS 2005
- Country
- TWO United States
- XERS United States
- Employees
- TWO N/A
- XERS N/A
- Industry
- TWO Real Estate Investment Trusts
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- TWO Real Estate
- XERS Health Care
- Exchange
- TWO Nasdaq
- XERS Nasdaq
- Market Cap
- TWO 1.1B
- XERS 1.3B
- IPO Year
- TWO 2009
- XERS 2018
- Fundamental
- Price
- TWO $9.66
- XERS $8.33
- Analyst Decision
- TWO Buy
- XERS Strong Buy
- Analyst Count
- TWO 8
- XERS 7
- Target Price
- TWO $12.50
- XERS $8.00
- AVG Volume (30 Days)
- TWO 1.9M
- XERS 2.1M
- Earning Date
- TWO 10-27-2025
- XERS 11-07-2025
- Dividend Yield
- TWO 16.18%
- XERS N/A
- EPS Growth
- TWO N/A
- XERS N/A
- EPS
- TWO N/A
- XERS N/A
- Revenue
- TWO $257,735,000.00
- XERS $246,025,000.00
- Revenue This Year
- TWO N/A
- XERS $43.89
- Revenue Next Year
- TWO N/A
- XERS $20.40
- P/E Ratio
- TWO N/A
- XERS N/A
- Revenue Growth
- TWO N/A
- XERS 35.62
- 52 Week Low
- TWO $9.50
- XERS $2.73
- 52 Week High
- TWO $14.28
- XERS $8.51
- Technical
- Relative Strength Index (RSI)
- TWO 42.15
- XERS 61.63
- Support Level
- TWO $9.60
- XERS $7.88
- Resistance Level
- TWO $10.22
- XERS $8.51
- Average True Range (ATR)
- TWO 0.17
- XERS 0.37
- MACD
- TWO -0.02
- XERS -0.01
- Stochastic Oscillator
- TWO 9.68
- XERS 83.05
About TWO Two Harbors Investment Corp
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. The majority of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).